X
CRL icon

Xponance’s Charles River Laboratories CRL Stock Holding History

Xponance’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Sell
5,302
-43
-0.8% -$7.66K 0.01% 727
2026
Q1 		$922K Buy
5,345
+1,191
+29% +$221K 0.01% 774
2025
Q4 		$829K Buy
4,154
+323
+8% +$58.6K 0.01% 742
2025
Q3 		$599K Sell
3,831
-507
-12% -$80.5K ﹤0.01% 901
2025
Q2 		$658K Sell
4,338
-46
-1% -$6.13K 0.01% 850
2025
Q1 		$660K Sell
4,384
-2,634
-38% -$442K 0.01% 846
2024
Q4 		$1.3M Sell
7,018
-251
-3% -$48.4K 0.01% 637
2024
Q3 		$1.43M Buy
7,269
+226
+3% +$47K 0.01% 609
2024
Q2 		$1.45M Sell
7,043
-130
-2% -$29.5K 0.01% 575
2024
Q1 		$1.94M Buy
7,173
+428
+6% +$102K 0.02% 525
2023
Q4 		$1.59M Sell
6,745
-644
-9% -$127K 0.02% 535
2023
Q3 		$1.45M Buy
7,389
+335
+5% +$68.8K 0.02% 545
2023
Q2 		$1.48M Sell
7,054
-4,811
-41% -$957K 0.02% 543
2023
Q1 		$2.39M Buy
11,865
+42
+0.4% +$9.52K 0.04% 415
2022
Q4 		$2.58M Buy
11,823
+1,027
+10% +$224K 0.04% 388
2022
Q3 		$2.13M Buy
10,796
+1,021
+10% +$220K 0.04% 375
2022
Q2 		$2.09M Buy
9,775
+1,516
+18% +$370K 0.04% 360
2022
Q1 		$2.35M Buy
8,259
+105
+1% +$32.4K 0.04% 338
2021
Q4 		$3.07M Buy
8,154
+811
+11% +$315K 0.05% 289
2021
Q3 		$3.03M Sell
7,343
-184
-2% -$76.4K 0.06% 263
2021
Q2 		$2.78M Sell
7,527
-2,229
-23% -$744K 0.05% 289
2021
Q1 		$2.83M Buy
9,756
+52
+0.5% +$14.5K 0.06% 256
2020
Q4 		$2.42M Buy
9,704
+13
+0.1% +$3.1K 0.05% 281
2020
Q3 		$2.19M Buy
9,691
+764
+9% +$159K 0.05% 271
2020
Q2 		$1.56M Buy
+8,927
New +$1.42M 0.04% 300

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Xponance's CRL Position: Q2 2026 in Review

Xponance reduced its Charles River Laboratories (CRL) stake by 0.8% in Q2 2026, selling an estimated $7.66K and leaving 5,302 shares worth $1.2M. The position accounts for 0.01% of the portfolio, ranked #727.

Xponance first reported a position in CRL in Q2 2020 and has held it in 25 quarters since. The position peaked at $3.07M in Q4 2021. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Xponance held 5,302 shares of Charles River Laboratories worth $1.2M as of Q2 2026.
  • Xponance sold 43 Charles River Laboratories shares in Q2 2026, an estimated $7.66K.
  • Charles River Laboratories made up 0.01% of Xponance's portfolio in Q2 2026, its #727 holding.
  • Xponance first reported a position in Charles River Laboratories in Q2 2020 and has held it in 25 quarters since.
  • Xponance's Charles River Laboratories position peaked at $3.07M in Q4 2021.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.